

Substance Use Disorder in Pregnancy

Julia Riddle MSc. DO
FP/OB/Addiction Medicine

2025 Rural Michigan Opioid and Substance Use Summit
July 17th, 2025

Objectives

- Quick Review of the Opioid Epidemic
- Discuss stigma in the Pregnant Population
- Review Recovery Based Language
- Understand Biology of Addiction
- Understanding Prescribing Best Practices
- Reviewed Medications Available
- Harm Reduction for Pregnancy
- Neonatal Opioid Withdrawal Syndrome
- Northern Michigan Treatment Options



Three Waves of the Rise in Opioid Overdose Deaths





Figure 2. National Drug Overdose Deaths*, Number Among All Ages, 1999-2022




*Includes deaths with underlying causes of unintentional drug poisoning (X40–X44), suicide drug poisoning (X60–X64), homicide drug poisoning (X85), or drug poisoning of undetermined intent (Y10–Y14), as coded in the International Classification of Diseases, 10th Revision. Source: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999–2022 on CDC WONDER Online Database, released 4/2024.



Pregnant Opioid Use

- Opioid use among pregnant women increased 131% 2010-2017-CDC
- Record high in 2020 drug overdose of all population and pregnant women in 2020.
- Methamphetamine, cocaine, and synthetic opioid fentanyl. - death certificates of 7,642 people who died or had just given birth 2017-2020, 1249 deaths. 1



Stigma Kills

stigmas affect



Self Doubt

inability to recover
“A lot of people doubt me
and say that I always get
clean and go back”



Fear

emotion caused by
anticipation or danger
“I was scared that DHHS
was going to come in and
take my baby”

Secrecy

Keeping secrets
“the new people in my life
don't know I'm on Suboxone
... I don't want to be
associated that way”




Resignation

acceptance of something
undesirable
“People judge you. Why try
my best to stay clean when
you get no support ”



Stigma experienced by rural pregnant women with substance use disorder: A systematic review and qualitative synthesis



Conclusions

- The stigma that pregnant women with SUD experience infiltrate communities in social and medical settings.
 - Viewed as “fallen women”
 - Medical personnel saying use of IV drugs why would they care about a needle poke.
 - Discontinuation of treatment if they became pregnant.
 - Feelings that they will be seen as drug seekers.
 - Distance of facilities that care for SUD patients
- While such stigma does not seem specific to rural populations, unique considerations complicate the effects of stigma on prenatal and SUD treatment, such as accessibility to treatment, lack of anonymity, and acceptability of treatment options available. ²

Interviews with pregnant/postpartum women

- **Melinda:** I would *never* advise somebody to have a child [at the hospital]. I thought I was helping my child by being honest during my pregnancy, I thought I was helping him if I was honest with my doctors. No, I wasn't. All I did was damage that relationship and our early bonding by letting them have that "in" to keep him from us. We could've, and we would have, taken better care of him than what they did, leaving him in his bassinet with a million other babies in there and not enough people to take care of all the babies. ³

Language Matters

Language is powerful – especially when talking about addictions.
Stigmatizing language perpetuates negative perceptions.

“Person first” language focuses on the person, not the disorder.

When Discussing Addictions...

SAY THIS NOT THAT

Person with a substance use disorder

Person living in recovery

Person living with an addiction

Person arrested for drug violation

Chooses not to at this point

Medication is a treatment tool

Had a setback

Maintained recovery

Positive drug screen

Addict, junkie, druggie

Ex-addict

Battling/suffering from an addiction

Drug offender

Non-compliant/bombed out


Medication is a crutch

Relapsed

Stayed clean

Dirty drug screen





Biology of addiction

- Multifaceted
- Lose control over their actions- rewires the brain
- Feel anxious/bad when not using.
- Repeated use damages the pre-frontal cortex
- Some genes maybe linked to addiction
- Younger people start increase risk as frontal cortex not fully developed and reward centers are in overdrive
- Trauma increases risk of addiction
- NOT A MORAL ISSUE

Symptoms of addiction

- sleep difficulties
- anxiety or depression
- memory problems
- mood swings (temper flare-ups, irritability, defensiveness)
- rapid increases in the amount of medication needed
- frequent requests for refills of certain medicines
- a person not seeming like themselves (showing a general lack of interest or being overly energetic)
- “doctor shopping” (moving from provider to provider in an effort to get several prescriptions for the same medication)
- use of more than one pharmacy
- false or forged prescription

How is a diagnosis made?

Taking the substance in larger amounts or for longer than you're meant to.

Wanting to cut down or stop using the substance but not managing to.

Spending a lot of time getting, using, or recovering from use of the substance.

Cravings and urges to use the substance.

Not managing to do what you should at work, home, or school because of substance use.

Continuing to use, even when it causes problems in relationships.

Giving up important social, occupational, or recreational activities because of substance use.

Using substances again and again, even when it puts you in danger.

Continuing to use, even when you know you have a physical or psychological problem that could have been caused or made worse by the substance.

Needing more of the substance to get the effect you want (tolerance).

Development of withdrawal symptoms, which can be relieved by taking more of the substance.



What do we do?

Stop cold
turkey

Wean down

Begin
medication
treatment

Offer harm
reduction

WHAT IS NALTREXONE?



NALTREXONE

Naltrexone was originally approved by the U.S. Food and Drug Administration (FDA) as a treatment for alcohol dependence, but people who are addicted to opioids may also benefit from this medication.

The medication is an opiate antagonist, meaning it works in the brain to prevent the euphoric effects of opioids. At the same time, it also decreases the desire to take opiates or drink alcohol.



REVIA



Revia is taken once daily by mouth

VIVITROL



once-monthly extended-release naltrexone injection

Methadone

What is Methadone?

Methadone is a long-acting opioid medication that is used as a pain reliever and, together with counseling and other psychosocial services, is used to treat people addicted to heroin and certain prescription drugs.

What is Methadone Maintenance Treatment (MMT)?

MMT helps normalize your body's neurological and hormonal functions that have been impaired by the use of heroin or misuse of other short-acting opioids.

Opioids are a group of drugs that act on the central nervous system. They include substances such as:

- codeine
- morphine
- heroin
- synthetic drugs such as:
 - oxycodone
 - oxycontin
 - hydrocodone
 - methadone

Appropriate Methadone Maintenance Treatment provides several benefits:

- Reduces or eliminates cravings for opioid drugs
- Prevents the onset of withdrawal for 24 hours or more
- Blocks the effects of other opioids
- Promotes increased physical and emotional health
- Raises overall quality of life

Buprenorphine/Naloxone

- Indications:
- Buprenorphine is a life-saving medicine. Strong evidence supports that it reduces death (overdose and all-cause mortality) by over two times.
- Buprenorphine's effects include pain relief, decreased withdrawal symptoms, and decreased opioid cravings. It does not tend to produce a high, and it is much less likely than other opioids to produce respiratory depression.
- At an effective dose, buprenorphine enables stabilization of neurobiologic brain processes and supports all the activities needed for recovery.
- When buprenorphine supports a person with an opioid use disorder to not use other opioids (except in specific cases of need with medical supervision), and go forward with recovery and responsible life activities, that person is in recovery, not active addiction.

Buprenorphine/Naloxone

- Pharmacology:
- Buprenorphine is a partial opioid agonist at the mu receptors. It is often combine with naloxone
- (buprenorphine-naloxone) to deter people from misusing it. The naloxone (aka narcan) is not active when given sublingually or swallowed. (It is added only to discourage people from crushing the drug and injecting. If injected, it would cause precipitated withdrawal.)
- 9

Summary of Medication



Medication assisted treatment

- Pharmacotherapy, combined with behavioral interventions, helps people who misuse opioids avoid experiencing withdrawal symptoms or overwhelming cravings when the opioid misuse is stopped.
- By blocking cyclic withdrawal symptoms associated with the misuse of short-acting opioids, methadone or buprenorphine can provide a more stabilized intrauterine environment.
- In addition, starting on pharmacotherapy can help the pregnant woman stop injecting drugs, a primary route of infection for people who use drugs.
- By controlling the symptoms of OUD (e.g., withdrawal, cravings), the pregnant woman can regain control, reengage in important obligations and activities in her life, and rebuild a stable social environment for herself and her family. Behavioral interventions are also recommended to provide maximum support for long-term recovery.
- Additional information on www.SAMHSA.gov/treatment. 10



Before

After



far away treatment/
no transportation

Treatment through
doctor



Less connection to
Family

Participating in
family events



Overdose

Says he'd be dead
without treatment



Moderate dependency

No use or
withdrawal symptoms




Risk of losing job

Stable job + Promotion





COMPARISON OF RELAPSE RATES BETWEEN DRUG ADDICTION AND OTHER CHRONIC ILLNESSES



Source: JAMA, 284:1689-1695, 2000

Harm Reduction

- Accepting that drug use (illicit and legal) is part of our world and that we can minimize harm instead of condemning it.
- Understand drug use as a complex, multi-faceted phenomenon and acknowledge that some ways of using drugs are clearly safer than others.
- Prioritize quality of life (at the individual and community level) over the cessation of drug use when evaluating intervention and policies.
- Calls for the non-judgmental, non-coercive provision of services and resources to people who use drugs (PWUD) in order to assist them in reducing harm.

Harm reduction services include...



Syringe Access



Syringe Disposal



Safer Drug Use



Naloxone



Medication Assisted Treatment



Supervised Consumption Services



Drop-In Centers



Housing First



Pharmacy Access



Referral & linkage

Ensuring that people who use drugs have a real voice in the creation of programs and policies designed to serve them

Affirms people who use drugs (PWUD) themselves as the primary agents of reducing the harms of their drug use and seeks to empower PWUD to share information and support each other in strategies which meet their actual conditions of use.


Recognizes that the realities of poverty, class, racism and other social inequalities affect both people's vulnerability to and capacity for effectively dealing with drug-related harm.

Does not attempt to minimize or ignore the real and tragic harm and danger that can be associated with illicit drug use. 11

Neonatal Opioid Withdrawal Syndrome

Neonatal Opioid Withdrawal Syndrome with Dr. Stephen Patrick

Diagnosis



- Tremors
- Increased muscle tone
- Decreased sleep
- High pitched cry
- Seizures



- Loose stools
- Feeding difficulties
- Excessive weight loss
- Vomiting



- Fever
- Sweating
- Yawning and sneezing
- Tachypnea
- Nasal stuffiness
- Nasal flaring

Diagnostic Pearl:



Toxicology testing can be performed with urine, meconium, or umbilical cord tissue. Testing rarely changes management.

Monitoring

Observe infants for 3-7 days depending on the type of opioid exposure

Standardized Scoring Systems

Modified Finnegan Score
MOTHER Neonatal Abstinence Measure
Eat, Sleep, Console

Use non-pharmacologic treatment for all infants with NOWS and medication only for severe withdrawal.



Managing Nows

Managing Neonatal Opioid Withdrawal Syndrome

Non-Pharmacologic Treatment



Keep mom and baby together

Provide a quiet and non-stimulating environment



Encourage breastfeeding when possible



Pharmacotherapy

Morphine
Buprenorphine
Methadone

Discharge Planning:

- 1 Infant shows no significant signs of withdrawal for 24-48 hours
- 2 Parents counseled on signs of withdrawal, safe sleep practices, and the usual newborn discharge counseling
- 3 Follow up appointment in 24-48 hours with pediatrician and home health nurse



Hane J, Patrick S, Chui C, Berk J. "Neonatal Opioid Withdrawal Syndrome: Eat, Sleep, Console, Repeat". The Cribsiders Pediatric Podcast.
<https://www.thecribsiders.com>

Infographic by
Dr. Jessica Hane
@jhanemd 

Eat Sleep Console

- A total of 1305 infants were enrolled. In an intention-to-treat analysis that included 837 infants who met the trial definition for medical readiness for discharge, the number of days from birth until readiness for hospital discharge was
- 8.2 in the Eat, Sleep, Console group and 14.9 in the usual-care group (adjusted
- mean difference, 6.7 days; 95% confidence interval [CI], 4.7 to 8.8), for a rate ratio
- of 0.55 (95% CI, 0.46 to 0.65; $P < 0.001$). The incidence of adverse outcomes was similar in the two groups. 12

Grand Traverse Women's Clinic

- Medication treatment specifically with Buprenorphine and Buprenorphine/Naloxone products and Naltrexone
- Offices in Traverse City, Beulah and Kalkaska
- Complete Obstetric Care
- Work with Munson Behavioral Health for Recovery Coaching, Psychiatry, and Counseling
- NICU has video describing treatment and NAS
- Do primary care and depression/Anxiety treatment
- Continue to work with women postpartum.
- Primary Care for Women
- Community health worker
- SUDHH health home



Munson Behavioral Health

- Medication treatment with Buprenorphine/Naloxone and Naltrexone
- Onsite counseling, recovery coaching, case management, Psychiatry
- Intensive out patient treatment
- Men and women
- Limited primary care
- SUDHH health home

NMSAS Recovery Center

- Medication treatment with all modalities including methadone
- Onsite counseling, recovery coaching, case management
- Men and women
- Limited primary care
- SUDHH health home






Summary of Michigan's attempt at COMBATING THE OPIOD EPIDEMIC

- Treatment Programs
- Syringe Service Programs (SSPs)
- Better Prescribing
- MAPS for Providers
- Drug Take-Back Locations
- Naloxone
- Michigan's Good Samaritan Law

Goals

- Health—overcoming or managing one's disease(s) or symptoms and making informed, healthy choices that support physical and emotional well-being.
- Home—having a stable and safe place to live.
- Purpose—conducting meaningful daily activities and having the independence, income, and resources to participate in society.
- Community—having relationships and social networks that provide support, friendship, love, and hope.



Conclusions

- Stabilizing fetal levels of opioids, help reduce repeated prenatal withdrawal
- Prenatal care appointments provide practitioners the opportunity to connect women to needed resources, to screen them for dangerous illnesses or injuries, to screen for intimate partner abuse victimization, and to implement many other public health interventions.
- Linking mothers to treatment for infectious diseases (e.g., HIV, HBV, HCV), reducing likelihood of transmittal to the unborn baby
- Providing opportunity for better prenatal care
- Improving long-term health outcomes for the mother and baby ¹³

Conclusions

- By adopting policies that scare women away from treatment, clinics and health organizations lose the opportunity to intervene and promote maternal and infant health.



Bibliography

1. Bruzelius E, Martins SS. US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020. *JAMA*. 2022;328(21):2159-2161. doi:10.1001/jama.2022.17045
2. Bright V, Riddle J, Kerver J. Stigma Experienced by Rural Pregnant Women with Substance Use Disorder: A Scoping Review and Qualitative Synthesis. *International Journal of Environmental Research and Public Health*. 2022; 19(22):15065. <https://doi.org/10.3390/ijerph192215065>
3. Stone, R. Pregnant women and substance use: fear, stigma, and barriers to care. *Health Justice* 3, 2 (2015). <https://doi.org/10.1186/s40352-015-0015-5>
4. [Biology of Addiction Drugs and Alcohol Can Hijack Your Brain https://newsinhealth.nih.gov/2015/10/biology-addiction](https://newsinhealth.nih.gov/2015/10/biology-addiction)
5. [What are the symptoms of addiction? https://www.medicalnewstoday.com/articles/323459#takeaway](https://www.medicalnewstoday.com/articles/323459#takeaway)
6. [DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationalehttps://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=23903334](https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=23903334)
7. [Naltrexone Treatment in West Palm Beach - CWC Recovery](#)
8. [Methadone Facts | Lakeview Center \(lakeviewcenter.org\)](#)
9. https://www.opioidlibrary.org/wp-content/uploads/2019/11/Englander-et-al.-JAM-2019_Appx-15_Buprenorphine-fact-sheet.docx.pdf
10. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition) How effective is drug addiction treatment? <https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/frequently-asked-questions/how-effective-drug-addiction-treatment>
11. <https://www.ieocc.org/news/harm-reduction-at-ieocc-in-2021>
12. Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal Author: Leslie W. Young, Songthip T. Ounpraseuth, Stephanie L. Merhar, et al Publication: The New England Journal of Medicine Publisher: Massachusetts Medical Society Date: Jun 22, 2023
13. "Publications and Digital Products." Treating Opioid Use Disorder During Pregnancy | SAMHSA Publications and Digital Products, <https://www.store.samhsa.gov/product/Treating-Opioid-Use-Disorder-During-Pregnancy/sma18-5071fsz>

